Therapy News and Research

RSS

Secure Tracks launches innovative new patient support system

Weight bearing gait aides such as conventional walkers and belts could quickly become a thing of the past in rehabilitation centers of hospitals as Secure Tracks today announced the launch of its innovative new patient support system. Customized for each hospital's unique needs, Secure Tracks is a purely mechanical system that consists of a ceiling-mounted monorail track, an exclusive trolley and a U-shaped support device that allows patients to stand completely upright and walk with a natural gait without the need for a harness.

13 Oct 2010

New global plan for elimination of TB

The world could be on its way towards eliminating tuberculosis (TB) if governments and donors fully invest in a plan released today by the Stop TB Partnership. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis for the first time identifies all the research gaps that need to be filled to bring rapid TB tests, faster treatment regimens and a fully effective vaccine to market.

13 Oct 2010

MetLife study finds Adult Day Services centers are increasing in the U.S.

There has been significant growth in the number of Adult Day Services centers in the U.S. over the past eight years, according to a new study by the MetLife Mature Market Institute. As reported in "The MetLife National Study of Adult Day Services: Providing Support to Individuals and Their Family Caregivers," there are more than 4,600 Adult Day Services (ADS) centers nationwide, a 35% increase since 2002.

13 Oct 2010

Scientists identify gene that could predict breast cancer patients' response to tamoxifen

Scientists have identified a gene which could help predict whether a breast cancer patient will respond to taking tamoxifen. The study, published in the British Journal of Cancer today (Wednesday), showed a potential link between the activity of a gene called BCAR4 and the likelihood that a breast cancer tumour will not respond to tamoxifen - widely used to treat women with breast cancer.

13 Oct 2010

ViiV Healthcare to expand Patient Assistance Program

ViiV Healthcare will expand its Patient Assistance Program effective January 1, 2011 and continue its Patient Savings Card program to help maintain access to HIV medicines for those most affected by the economic downturn in the United States. Specifically, ViiV Healthcare will launch the ViiV Healthcare Patient Assistance Program with an increased maximum household income level for enrollment and is piloting membership in the Welvista program, a nonprofit program to facilitate access to HIV medications for individuals currently on ADAP waiting lists.

13 Oct 2010

Bariatric surgery reduces healthcare costs for morbidly obese diabetics

New data presented today at Obesity 2010, the 28th annual scientific meeting of The Obesity Society, find that bariatric surgery is associated with reduced healthcare costs for diabetes patients who are morbidly obese.

13 Oct 2010

Physicians anticipate new oral therapies for multiple sclerosis patients

Physicians are anticipating the arrival of new oral therapies for multiple sclerosis patients, with initial research showing very high awareness of oral candidates, particularly Novartis' Gilenya, which received FDA approval for relapsing forms of the disease in late September. The majority of neurologists expect Gilenya to be very useful as a therapy and trial of the drug is predicted to be strong, according to new research by GfK HealthCare.

13 Oct 2010

Study demonstrates chitosan/IL-12 is an effective anti-tumor immunotherapy

A new study by a University of Arkansas biomedical engineer and his colleagues at the National Cancer Institute demonstrates further promise for chitosan/interleukin-12 as an effective anti-tumor immunotherapy.

13 Oct 2010

BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA

BioRx, a specialty pharmacy company, has received limited distribution rights from Baxter International Inc. for a new drug, GLASSIA™ [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid, ready-to-use treatment for alpha-1 antitrypsin deficiency (AATD) in the United States. AATD is a genetic disorder that causes low levels of alpha 1-antitrypsin, resulting in emphysema. AATD is also referred to as "genetic" or "congenital" emphysema.

From Baxter International Inc. 13 Oct 2010

Ocular Therapeutix completes Proof of Principle clinical study with moxifloxacin punctum plug

Ocular Therapeutix, Inc. announced today the completion of a successful Proof of Principle clinical study with their novel sustained drug delivery moxifloxacin punctum plug.

13 Oct 2010

Archimedes publishes results from FPNS Phase III clinical study for breakthrough cancer pain

Archimedes Pharma, an emerging specialty pharma company focused on oncology, pain, neurology and critical care sectors, today announced publication of results from a Phase III, long-term safety, tolerability and consistency of effect, clinical study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain (BTCP).

13 Oct 2010

New cancer initiative may promote rapid drug development

Greenville Hospital System University Medical Center (GHS) unveiled details of its new Institute for Translational Oncology Research, a visionary cancer initiative that will help pave the way for new breakthroughs in rapid drug development, diagnostic discovery and advanced cancer care. ITOR is part of the GHS Cancer Center, a recognized regional multi-disciplinary center.

13 Oct 2010

Researchers develop new therapy to overcome tissue incompatibility in kidney transplantation

Donor kidneys can be successfully transplanted even if there is strong tissue incompatibility between donor and recipient. An interdisciplinary working group headed by Dr. Christian Morath, senior consultant at the Department of Nephrology at Heidelberg University Hospital (Medical Director: Professor Dr. Martin Zeier) and Professor Dr. Caner S-sal, head of antibody laboratory in the Department of Transplantation Immunology, showed in a study of 34 sensitized high-risk patients that the success rate in these patients was not different from the success rate of patients with a low immunological risk.

13 Oct 2010

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today it has received approval from the first Taiwanese Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Oct 2010

DoD awards $1.5 million grant to study nanoemulsion-based therapies for preventing burn wound infections

Researchers from NanoBio Corporation and the University of Michigan Medical School today announced the receipt of a $1.5 million grant from the Department of Defense (DoD) to study the use of nanoemulsion-based therapies for protection against burn and wound infections.

13 Oct 2010

Officials discuss leadership, donor commitments, eliminating leprosy at start of WHO Western Pacific Region Committee Session

The WHO "must demonstrate strong leadership backed by impeccable technical competency, [Malaysian] Prime Minister Datuk Seri Najib Tun Razak said" at the opening ceremony of the 61st Session of the WHO Regional Committee for the Western Pacific Monday, Bernama reports.

13 Oct 2010

Immunomedics receives additional patent claims for antibody therapy

Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that additional claims for the patent family "Method and kit for imaging and treating organs and tissue," were issued as U.S. Patent No. 7,811,570.

13 Oct 2010

Scientists design synthetic molecule to protect liver cancer cells from toxic effects of chemotherapy

Scientists have found that a synthetic molecule they designed can block activation of a gene in liver cancer cells, halting a process that allows some of those cancer cells to survive chemotherapy.

13 Oct 2010

US Oncology enrolls 1,000th patient in Phase I clinical trial

US Oncology, Inc., the nation's leading integrated oncology company, announced today that it has enrolled the 1,000th patient in a Phase I clinical trial through its US Oncology Research Network. Phase I clinical trials present special challenges, including increased safety concerns, higher variability of patient disease, more complex trial designs, and some first-in-human trials, making Phase I trials more difficult to operate in the community setting.

13 Oct 2010

HSV1716 clinical trial for childhood cancer receives FDA grant

A clinical trial testing a genetically reprogrammed herpes simplex virus as treatment for deadly forms of childhood cancer has received a U.S. Food and Drug Administration grant to support the research.

13 Oct 2010

Therapy News and Research

Secure Tracks launches innovative new patient support system

New global plan for elimination of TB

MetLife study finds Adult Day Services centers are increasing in the U.S.

Scientists identify gene that could predict breast cancer patients' response to tamoxifen

ViiV Healthcare to expand Patient Assistance Program

Bariatric surgery reduces healthcare costs for morbidly obese diabetics

Physicians anticipate new oral therapies for multiple sclerosis patients

Study demonstrates chitosan/IL-12 is an effective anti-tumor immunotherapy

BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA

Ocular Therapeutix completes Proof of Principle clinical study with moxifloxacin punctum plug

Archimedes publishes results from FPNS Phase III clinical study for breakthrough cancer pain

New cancer initiative may promote rapid drug development

Researchers develop new therapy to overcome tissue incompatibility in kidney transplantation

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

DoD awards $1.5 million grant to study nanoemulsion-based therapies for preventing burn wound infections

Officials discuss leadership, donor commitments, eliminating leprosy at start of WHO Western Pacific Region Committee Session

Immunomedics receives additional patent claims for antibody therapy

Scientists design synthetic molecule to protect liver cancer cells from toxic effects of chemotherapy

US Oncology enrolls 1,000th patient in Phase I clinical trial

HSV1716 clinical trial for childhood cancer receives FDA grant

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News